The antidepressant Prozac may help to curb disease activity in the relapsing remitting form of multiple sclerosis (MS), reveals preliminary research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.
The research team randomly allocated 40 patients with the relapsing remitting form of MS to treatment with either 20 mg daily of fluoxetine (Prozac) or an inactive substance (placebo) for a period of 24 weeks.
Detailed brain scans (magnetic resonance images or MRI) every four weeks were used to check for new areas of neurological inflammation, a hallmark of active disease.
In total, 38 patients—19 in each group—completed the study. The scans showed that those in the placebo group had more new areas of inflammation than those treated with Prozac.
The effects began to become evident after eight weeks, which corresponds to the time the selective serotonin reuptake inhibitor (SSRI) class of drugs, of which Prozac is one, start to work on relieving depression.
The average number of new areas affected was more than five in the group given the placebo compared with just under two in the group given Prozac.
One in four scans from patients treated with Prozac showed new areas of inflammation compared with four out of 10 of those taking placebo.
During the last 16 weeks of treatment, almost two thirds of patients (63%) in the group given Prozac had no new areas of inflammation compared with only one in four (26%) in the group given placebo.
The authors caution that their study was small, and larger studies would be needed before firm conclusions could be drawn.
But they conclude that their results are “sufficiently encouraging to justify further studies with fluoxetine in patients with MS,” adding that higher doses and treatment combinations with other drugs that alter the immune response, should be considered.
Source: British Medical Journal
Related stories:
Teens with treatment-resistant depression more likely to improve with combination therapy
Teens with difficult-to-treat depression who do not respond to a first antidepressant medication are more likely to get well if they switch to another antidepressant medication and add psychotherapy rather than just switching to another antidepressant, according to a large, multi-site trial funded by the National Institutes of Health’s National Institute of Mental Health (NIMH). The results of the Treatment of SSRI-resistant Depression in Adolescents (TORDIA) trial were published February 27, 2008, in the
Journal of the American Medical Association.
Who benefits from antidepressants?
A new study published today in
PLoS Medicine suggests that antidepressants only benefit some, very severely depressed patients.
As depression symptoms improve with antidepressants, hopelessness can linger
People taking medication for depression typically see a lot of improvements in their symptoms during the first few months, but lagging behind other areas is a sense of hopefulness, according to new research from the University of Michigan Health System.
Research Aims to Find Most Effective Family-Based Treatment for Anorexia
Experts no longer consider the family to be the cause of a young person’s onset of anorexia; instead, the family is being looked to as a solution for this serious and potentially lethal disease.
Scientists develop non-invasive method to track nerve-cell development in live human brain
A team of scientists including researchers at Cold Spring Harbor Laboratory (CSHL) have identified and validated the first biomarker that permits neural stem and progenitor cells (NPCs) to be tracked, non-invasively, in the brains of living human subjects. This important advance could lead to significantly better diagnosis and monitoring of brain tumors and a range of serious neurological and psychiatric disorders.
Study: cannabis a double-edged sword
A new neurobiological study has found that a synthetic form of THC, the active ingredient in cannabis, is an effective anti-depressant at low doses. However, at higher doses, the effect reverses itself and can actually worsen depression and other psychiatric conditions like psychosis.
Think herbal supplements are safe? Think again, book by SLU doctor says
People are mixing supplements, herbs and over-the-counter medications and prescription drugs to cure themselves of ills, unaware that they could be making themselves sicker, says George Grossberg, M.D., director of the division of geriatric psychiatry at Saint Louis University.
New insights into autoimmunity and depression
Systemic lupus erythomatosus (SLE), often simply called lupus, is a complex autoimmune disease marked by joint pain, skin rashes, extreme fatigue, and depression, among other symptoms. Some studies have described a possible link between SLE’s most severe psychiatric manifestation, psychosis, and a protein autoantibody associated with the central nervous system, anti-ribosomal P.